1. Home
  2. EARN vs XBIT Comparison

EARN vs XBIT Comparison

Compare EARN & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EARN

Ellington Residential Mortgage REIT of Beneficial Interest

HOLD

Current Price

$4.44

Market Cap

169.8M

Sector

Real Estate

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.33

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EARN
XBIT
Founded
2012
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Pharmaceuticals and Biotechnology
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
169.8M
74.4M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
EARN
XBIT
Price
$4.44
$2.33
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$5.38
N/A
AVG Volume (30 Days)
348.6K
31.8K
Earning Date
06-16-2026
05-08-2026
Dividend Yield
20.51%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.69
N/A
Revenue Next Year
$19.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.27
$2.09
52 Week High
$6.08
$3.61

Technical Indicators

Market Signals
Indicator
EARN
XBIT
Relative Strength Index (RSI) 40.45 38.43
Support Level $4.31 $2.26
Resistance Level $4.78 $2.67
Average True Range (ATR) 0.11 0.04
MACD 0.00 0.00
Stochastic Oscillator 19.57 15.00

Price Performance

Historical Comparison
EARN
XBIT

About EARN Ellington Residential Mortgage REIT of Beneficial Interest

Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: